Nektar Securities Suit Urges Investors To Seek Lead‑Plaintiff Status Before May 5

Overview

• Competing investor law firms, which issued fresh notices Monday, called on shareholders to move by the May 5 court deadline to seek the lead‑plaintiff role.
• The filed complaint says REZOLVE‑AA enrollment did not follow trial instructions and protocol standards, which likely weakened the data and overstated the study’s prospects.
• The putative class covers purchases from February 26 to December 15, 2025, and the suit says losses followed a December 16 disclosure about ineligible patients and missed statistical goals.
• Benzinga reports Nektar’s shares fell 7.77% on December 16, dropping from $53.30 to $49.16 after the corrective disclosure
• No class has been certified, so investors are not represented unless they retain counsel, and any qualified firm may seek appointment to lead the case under the PSLRA.